Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 3, 2012, Pages 840-849

  Cunningham, Colin S ^a   Javors, Martin A ^a   McMahon, Lance R ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; COCAINE; COTININE; CYTISINE; DIHYDRO BETA ERYTHROIDINE; DOPAMINE; MECAMYLAMINE; MIDAZOLAM; NICOTINE; VARENICLINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SALIVA ANALYSIS; TOBACCO DEPENDENCE;

ALKALOIDS; ANIMALS; AZOCINES; BENZAZEPINES; COCAINE; CONDITIONING, OPERANT; DISCRIMINATION LEARNING; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; FEMALE; HYPNOTICS AND SEDATIVES; MACACA MULATTA; MALE; MECAMYLAMINE; MIDAZOLAM; NICOTINE; NICOTINIC AGONISTS; QUINOLIZINES; QUINOXALINES; RECEPTORS, NICOTINIC;

EID: 84861551045     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.193078     Document Type: Article

References (40)

1. Buchhalter AR, Fant RV, and Henningfield JE (2008) Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 68:1067-1088. (Pubitemid 351693676)
2. Chandler CJ and Stolerman IP (1997) Discriminative stimulus properties of the nicotinic agonist cytisine. Psychopharmacology 129:257-264. (Pubitemid 27085396)
3. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, et al. (2005) Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474-3477. (Pubitemid 40664098)
4. Dale HH (1914) The action of certain esters and ethers of choline and their relation to muscarine. J Pharmacol Exp Ther 6:147-190.
5. de la Garza R and Johanson CE (1982) Effects of haloperidol and physostigmine on self-administration of local anesthetics. Pharmacol Biochem Behav 17:1295-1299.
6. Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, and Benowitz NL (2004) Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 76:64-72. (Pubitemid 38844735)
7. Gauvin DV and Young AM (1989) Evidence for perceptual masking of the discriminative morphine stimulus. Psychopharmacology 98:212-221. (Pubitemid 19137734)
8. Gommans J, Stolerman IP, and Shoaib M (2000) Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice. Neuropharmacology 39:2840-2847.
9. Gotti C, Guiducci S, Tedesco V, Corbioli S, Zanetti L, Moretti M, Zanardi A, Rimondini R, Mugnaini M, Clementi F, et al. (2010) Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area α6β2*receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J Neurosci 30:5311-5325.
10. Gotti C, Zoli M, and Clementi F (2006) Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27:482-491. (Pubitemid 44251225)
11. Gould RW, Czoty PW, Nader SH, and Nader MA (2011) Effects of varenicline on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 339:678-686.
12. Institute for Laboratory Animal Research (2011) Guide for the Care and Use of Laboratory Animals 8th ed. Institute for Laboratory Animal Research, Division of Earth and Life Sciences, National Research Council, Washington, DC.
13. Jarvis MJ, Primatesta P, Erens B, Feyerabend C, and Bryant A (2003) Measuring nicotine intake in population surveys: comparability of saliva cotinine and plasma cotinine estimates. Nicotine Tob Res 5:349-355. (Pubitemid 36764030)
14. Jutkiewicz EM, Brooks EA, Kynaston AD, Rice KC, and Woods JH (2011) Patterns of nicotinic receptor antagonism: nicotine discrimination studies. J Pharmacol Exp Ther 339:194-202.
15. Kenakin T (1997) Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott Williams & Wilkins, New York.
16. Lelas S, Gerak LR, and France CP (1999) Discriminative-stimulus effects of triazolam and midazolam in rhesus monkeys. Behav Pharmacol 10:39-50. (Pubitemid 29106287)
17. LeSage MG, Shelley D, Ross JT, Carroll FI, and Corrigall WA (2009) Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacol Biochem Behav 91:461-467.
18. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, and Tyndale RF (2006) Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11:400-409.
19. Mariathasan EA and Stolerman IP (1993) Overshadowing of nicotine discrimination in rats: a model for behavioural mechanisms of drug interactions? Behav Pharmacol 4:209-215. (Pubitemid 23181740)
20. Morrison CF and Stephenson JA (1969) Nicotine injections as the conditioned stimulus in discrimination learning. Psychopharmacologia 15:351-360.
21. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, and Kuroiwa Y (1996) Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 277:1010-1015.
22. Polosa R and Benowitz NL (2011) Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci 32:281-289.
23. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, et al. (2007) Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985-994. (Pubitemid 46227486)
24. Rollema H, Shrikhande A, Ward KM, Tingley FD 3rd, Coe JW, O'Neill BT, Tseng E, Wang EQ, Mather RJ, Hurst RS, et al. (2010) Pre-clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol 160: 334-345.
25. Romano C, Goldstein A, and Jewell NP (1981) Characterization of the receptor mediating the nicotine discriminative stimulus. Psychopharmacology 74:310-315. (Pubitemid 11003747)
26. Schoedel KA, Sellers EM, Palmour R, and Tyndale RF (2003) Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol Pharmacol 63:96-104. (Pubitemid 36043813)
27. Shoaib M, Sidhpura N, and Shafait S (2003) Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology 165:405-412. (Pubitemid 36223082)
28. Shoaib M, Zubaran C, and Stolerman IP (2000) Antagonism of stimulus properties of nicotine by dihydro-β-erythroidine (DHßE) in rats. Psychopharmacology 149:140-146. (Pubitemid 30238951)
29. Slemmer JE, Martin BR, and Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321-327.
30. Smith JW and Stolerman IP (2009) Recognising nicotine: the neurobiological basis of nicotine discrimination. Handb Exp Pharmacol 192:295-333.
31. Stolerman IP, Chandler CJ, Garcha HS, and Newton JM (1997) Selective antagonism of behavioural effects of nicotine by dihydro-β-erythroidine in rats. Psychopharmacology 129:390-397. (Pubitemid 27093003)
32. Struthers AM, Wilkinson JL, Dwoskin LP, Crooks PA, and Bevins RA (2009) Mecamylamine, dihydro-β-erythroidine, and dextromethorphan block conditioned responding evoked by the conditional stimulus effects of nicotine. Pharmacol Biochem Behav 94:319-328.
33. Swan GE, Habina K, Means B, Jobe JB, and Esposito JL (1993) Saliva cotinine and recent smoking-evidence for a nonlinear relationship. Public Health Rep 108: 779-783. (Pubitemid 24015126)
34. Takada K, Hagen TJ, Cook JM, Goldberg SR, and Katz JL (1988) Discriminative stimulus effects of intravenous nicotine in squirrel monkeys. Pharmacol Biochem Behav 30:243-247. (Pubitemid 19268817)
35. Tallarida RJ (2000) Drug Synergism and Dose-Effect Data Analysis. Chapman Hall/CRC Press, Boca Raton, FL.
36. Varanda WA, Aracava Y, Sherby SM, VanMeter WG, Eldefrawi ME, and Albuquerque EX (1985) The acetylcholine receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist. Mol Pharmacol 28:128-137. (Pubitemid 16244112)
37. Wallace TL and Porter RH (2011) Targeting the nicotinic α7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 82:891-903.
38. Wiley JL, Lavecchia KL, Martin BR, and Damaj MI (2002) Nicotine-like discriminative stimulus effects of bupropion in rats. Exp Clin Psychopharmacol 10:129-135. (Pubitemid 34507144)
39. Wilkinson JL, Carroll FI, and Bevins RA (2010) An investigation of bupropion substitution for the interoceptive stimulus effects of nicotine. J Psychopharmacol 24:817-828.
40. Williams M and Robinson JL (1984) Binding of the nicotinic cholinergic antagonist, dihydro-β-erythroidine, to rat brain tissue. J Neurosci 4:2906-2911. (Pubitemid 15191160)